Minor
Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Not Yet Recruiting
Rui-hua Xu, MD, PhDPhase 2 NCT06329947 Registry history of NCT06329947 on ClinicalTrials.gov (opens the registry)
Changed